Exelixis, Inc. (NASDAQ:EXEL) is anticipated to report earnings of 121.51% per share for next year, according to research brokerages covering the stock. Triple Frond Partners Llc bought 500,000 shares as the company's stock declined 7.92% while stock markets rallied.
Other institutional investors have also recently bought and sold shares of the company. Macquarie Group Ltd. boosted its holdings in shares of Exelixis by 811.5% in the 3rd quarter. Fisher Asset Management LLC acquired a new stake in shares of Exelixis in the third quarter valued at approximately $213,000.
Legacy Private Trust decreased Lowes Cos Inc (LOW) stake by 41.15% reported in 2017Q3 SEC filing. Following the completion of the transaction, the director now directly owns 64,829 shares of the company's stock, valued at $1,964,318.70. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows "Sell" signal. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
In other news, Director Alan M. Garber sold 15,000 shares of the firm's stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $24.73, for a total value of $370,950.00. The disclosure for this sale can be found here. American Century Companies Inc. now owns 1,469,945 shares of the biotechnology company's stock worth $44,686,000 after acquiring an additional 1,190,691 shares during the last quarter. SunTrust Banks reiterated a "buy" rating and issued a $38.00 price target on shares of Exelixis in a research report on Thursday, December 21st. BidaskClub upgraded shares of Exelixis from a "hold" rating to a "buy" rating in a research note on Friday, January 5th. Stifel Nicolaus maintained it with "Hold" rating and $26.0 target in Thursday, September 7 report. Oppenheimer restated a "hold" rating on shares of Exelixis in a research note on Thursday, January 4th. Zacks Investment Research upgraded Exelixis from a "hold" rating to a "strong-buy" rating and set a $35.00 target price on the stock in a report on Tuesday, January 2nd. Finally, UBS Group upgraded shares of Exelixis from a "market perform" rating to an "outperform" rating in a research note on Tuesday, February 27th. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and nine have issued a buy rating to the stock. Exelixis has an average rating of "Hold" and a consensus target price of $34.10.
Exelixis, Inc. (EXEL) opened the session with a $24.92 price tag, later ranging from $24.53 to $25.3, the range at which the stock has traded at throughout the day. The company saw 3.32 million shares trade hands over the course of the day. Exelixis has a 52-week low of $18.03 and a 52-week high of $32.50. Current price places the company's stock 16.54% away from its 200-day simple moving average, -1.32%, away from the 50-day average and also -0.61% away from 20-day average.
Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Monday, February 26th.
Earnings per Share (EPS) are the part of a company's profit allocated to respectively outstanding share of common stock. The business had revenue of $120.10 million for the quarter, compared to the consensus estimate of $120.25 million. Analyst's mean target price for Exelixis, Inc. is $34.63. During the same quarter a year ago, the business earned $0.12 earnings per share.
Analysts are expecting average earnings estimates of $0.14 for the current quarter based on the opinion of 10 analysts, relating to high earnings per share estimates of $0.2 and low estimates of $0.05, however Exelixis Inc (NASDAQ:EXEL) reported $0.05 earnings per share for the same quarter previous year.
TRADEMARK VIOLATION WARNING: This story was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of United States and worldwide trademark & copyright legislation. Ghost Tree Ltd Liability invested 0.28% of its portfolio in Exelixis, Inc. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer.